Cargando…

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

BACKGROUNDS AND AIMS: Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gigante, Elia, Hobeika, Christian, Le Bail, Brigitte, Paradis, Valérie, Tougeron, David, Lequoy, Marie, Bouattour, Mohamed, Blanc, Jean-Frederic, Ganne-Carrié, Nathalie, Tran, Henri, Hollande, Clémence, Allaire, Manon, Amaddeo, Giuliana, Regnault, Hélène, Vigneron, Paul, Ronot, Maxime, Elkrief, Laure, Verset, Gontran, Trepo, Eric, Zaanan, Aziz, Ziol, Marianne, Ningarhari, Massih, Calderaro, Julien, Edeline, Julien, Nault, Jean-Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485952/ https://www.ncbi.nlm.nih.gov/pubmed/36158591 http://dx.doi.org/10.1159/000525488

Ejemplares similares

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
por: Salimon, Maëva, et al.
Publicado: (2018)

Importance of surgical margin in the outcomes of hepatocholangiocarcinoma
por: Ma, Ka Wing, et al.
Publicado: (2017)

Retinal and vitreous metastases from hepatocholangiocarcinoma
por: Praidou, Anna, et al.
Publicado: (2017)

A rare and distinct hepatic tumor: Hepatocholangiocarcinoma
por: Limaiem, Faten, et al.
Publicado: (2021)

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area
por: Amaddeo, Giuliana, et al.
Publicado: (2020)

Combined Hepatocholangiocarcinoma Associated with Humoral Hypercalcemia of Malignancy and Chronic Inflammatory Demyelinating Polyneuropathy
por: Colunga Biancatelli, Ruben Manuel Luciano, et al.
Publicado: (2019)

Clinical characterization and therapeutic targets of vitamin A in patients with hepatocholangiocarcinoma and coronavirus disease
por: Liang, Xiao, et al.
Publicado: (2021)

Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting
por: Falette-Puisieux, Manon, et al.
Publicado: (2023)

Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation
por: Gigante, Elia, et al.
Publicado: (2022)

Esophageal metastasis of stem cell-subtype hepatocholangiocarcinoma: Rare presentation of a rare tumor
por: Salimon, Maëva, et al.
Publicado: (2018)

Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma
por: Saint, Angélique, et al.
Publicado: (2020)

New insights into the pathophysiology and clinical care of rare primary liver cancers
por: Gigante, Elia, et al.
Publicado: (2020)

Macrotrabecular-Massive Hepatocellular Carcinoma: Light and Shadow in Current Knowledge
por: Sessa, Anna, et al.
Publicado: (2022)

In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?
por: Bucalau, Ana-Maria, et al.
Publicado: (2021)

Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Tougeron, D, et al.
Publicado: (2014)

Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry
por: de Baere, Thierry, et al.
Publicado: (2020)

Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas
por: Amaddeo, Giuliana, et al.
Publicado: (2015)

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)
por: Sidali, Sabrina, et al.
Publicado: (2023)

Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma
por: Péneau, Camille, et al.
Publicado: (2022)

Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Ramtohul, Toulsie, et al.
Publicado: (2022)

Molecular classification of hepatocellular adenomas: impact on clinical practice
por: Védie, Anne-Laure, et al.
Publicado: (2018)

Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS
por: Cannella, Roberto, et al.
Publicado: (2021)

New concepts in the treatment of hepatocellular carcinoma
por: Sidali, Sabrina, et al.
Publicado: (2022)

Duodenal Hemorrhage Due to an Invasive Hepatocellular Carcinoma Controlled by Transarterial Embolization
por: Deforche, Maxime, et al.
Publicado: (2022)

Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas
por: Chopinet, Sophie, et al.
Publicado: (2021)

Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma
por: Mouhoubi, Nesrine, et al.
Publicado: (2022)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
por: Pernot, Simon, et al.
Publicado: (2018)

Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
por: Hadefi, Alia, et al.
Publicado: (2021)

Patients’ Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life
por: Muzellec, Léa, et al.
Publicado: (2021)

Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer‐specific and overall mortality: A modeling approach
por: Ningarhari, Massih, et al.
Publicado: (2022)

Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes
por: Bucalau, Ana-Maria, et al.
Publicado: (2020)

Transarterial Chemoembolization with Anthracyclines-Loaded Polyethylene Glycol Drug Eluting Microspheres for the Treatment of Hepatocellular Carcinoma: A Pooled Multicentric Analysis of Survival in 580 Patients
por: Veloso Gomes, Filipe, et al.
Publicado: (2023)

Pathologic and molecular features of hepatocellular carcinoma: An update
por: Vij, Mukul, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety
por: Roquette, Isaure, et al.
Publicado: (2022)

Exploring the best treatment options for BRAF-mutant metastatic colon cancer
por: Taieb, Julien, et al.
Publicado: (2019)

Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
por: Charles Nault, Jean, et al.
Publicado: (2013)

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
por: Nault, Jean Charles, et al.
Publicado: (2013)

Management of splanchnic vein thrombosis
por: Elkrief, Laure, et al.
Publicado: (2023)

Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres
por: Garin, Etienne, et al.
Publicado: (2015)

CAR-T cells and BiTEs in solid tumors: challenges and perspectives
por: Edeline, Julien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7ludog32g3l9t07kme628astqi